Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference

Rhea-AI Summary

Oculis (Nasdaq: OCS) will participate in a fireside chat at the 47th Annual Goldman Sachs Global Healthcare Conference on June 9 at 4:00 p.m. ET in Miami, FL.

Management will discuss late-stage assets Privosegtor and Licaminlimab, key trials, funding and upcoming pivotal readouts.

News Market Reaction – OCS

-4.46%

12 alerts

-4.46% Session close to close

+9.4% Peak Tracked

-2.2% Trough Tracked

$730.23M Market Cap

0.5x Rel. Volume

In the Jun 8 session, OCS declined 4.46%, reflecting a moderate negative market reaction. Argus tracked a peak move of +9.4% during that session. Argus tracked a trough of -2.2% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement centers on Oculis’ participation in a major healthcare conference to showcase its ...

Analysis

This announcement centers on Oculis’ participation in a major healthcare conference to showcase its late-stage portfolio, particularly Privosegtor and Licaminlimab, tied to a potential U.S. market of $7B+. The update follows recent shifts away from OCS-01 after Phase 3 setbacks and significant equity financing activity. Investors may focus on clarity around registrational programs, upcoming pivotal readouts, and how existing capital resources are allocated across neuro-ophthalmic and dry eye disease indications.

Key Figures

U.S. market opportunity: $7B+ Conference edition: 47th Conference time: June 9, 4:00pm ET

3 metrics

U.S. market opportunity $7B+ Privosegtor potential market in optic neuropathies cited in conference press release

Conference edition 47th 47th Annual Goldman Sachs Global Healthcare Conference

Conference time June 9, 4:00pm ET Scheduled time for Oculis fireside chat at conference

Historical Context

5 past events · Latest: May 29 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 29	PDMR RSU transaction	Neutral	-36.1%	Disclosure of RSU vesting and settlement for a company director.
May 29	Phase 3 trial miss	Negative	-23.4%	OCS-01 Phase 3 DIAMOND trials failed primary and key visual endpoints.
May 28	PDMR RSU transaction	Neutral	-23.4%	RSU vesting and settlement for director Arshad Khanani disclosed.
May 15	Director equity awards	Neutral	-7.3%	Multiple director equity incentives and RSU vestings reported for PDMRs.
May 14	AGM and governance	Neutral	+0.2%	AGM approvals, new director election, capital band and conditional capital changes.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has often been followed by sharp downside moves, including large selloffs on neutral governance items and on the failed OCS-01 Phase 3 trials.

Recent Company History

Over the past month, Oculis has shifted from disappointing Phase 3 DIAMOND results for OCS-01 in diabetic macular edema, which saw a -23.42% reaction and a strategic pivot toward Privosegtor and Licaminlimab, to several PDMR RSU vesting disclosures that also coincided with notable declines (one at -36.09%). The May 2026 AGM approved all items, including new board member Gregory D. Perry and expanded share authorizations. Today’s conference appearance emphasizes the late-stage portfolio that management has recently prioritized.

Key Terms

breakthrough therapy designation, priority medicines (prime) designation, optic neuritis, optic neuropathies, +2 more

6 terms

breakthrough therapy designation regulatory

"Privosegtor, a novel neuroprotective candidate which received Breakthrough Therapy designation from the U.S."

A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.

priority medicines (prime) designation regulatory

"and Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for optic neuritis"

A priority medicines (PRIority MEdicines, PRIME) designation is a regulatory label given to a drug candidate that addresses a serious unmet medical need, granting the developer extra scientific guidance and faster review from health authorities. For investors, it signals lower regulatory risk and the potential for quicker approval and market access—think of it as a VIP pass through the approval process that can speed revenue potential and improve the investment outlook.

optic neuritis medical

"PRIME) designation from the European Medicines Agency (EMA) for optic neuritis (ON), in the PIONEER"

Inflammation of the optic nerve that can cause sudden vision loss, blurring, or eye pain, often like a camera lens fogging or an electrical wire briefly losing connection. It matters to investors because optic neuritis can signal safety issues for drugs or devices, affect regulatory approval, drive legal or clinical costs, and influence demand for treatments and diagnostic services—so reports of cases can move stock prices in healthcare and biotech names.

optic neuropathies medical

"PIONEER registrational program to address unmet needs for two optic neuropathies and to unlock"

Optic neuropathies are conditions in which the optic nerve—the cable that carries visual information from the eye to the brain—is damaged, causing reduced vision, blind spots, or color loss. For investors, these disorders matter because they create markets for drugs, devices, diagnostics and surgeries, influence regulatory approvals and reimbursement, and can affect a company's clinical trial prospects and potential revenues much like a critical fault in an electrical cable drives demand for repairs and replacements.

dry eye disease medical

"Licaminlimab, a topical anti-TNFα being evaluated in the PREDICT-1 registrational trial as the first genotype-based precision medicine in dry eye disease (DED)."

Dry eye disease is a chronic condition where the eyes do not make enough tears or the tears evaporate too quickly, causing irritation, blurred vision and sensitivity to light — imagine having tiny grains of sand or a windshield with streaks that never clear. It matters to investors because it creates steady demand for prescription drugs, medical devices and diagnostic tests; treatments can be long‑term, subject to regulatory approval and insurance coverage, and successful products can capture large, recurring revenue streams.

anti-tnfα medical

"Licaminlimab, a topical anti-TNFα being evaluated in the PREDICT-1 registrational trial"

Anti-TNFα refers to drugs that block the activity of tumor necrosis factor alpha, a protein that drives inflammation in conditions like rheumatoid arthritis and inflammatory bowel disease. For investors, these therapies matter because they represent large, durable drug markets, carry distinct regulatory and safety risks, and face competition from new entrants and lower-cost biosimilars—factors that directly affect revenue, approval timelines, and long-term profitability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that Oculis’ management will participate in a fireside chat at the 47^th Annual Goldman Sachs Global Healthcare Conference. 

The Company will provide an overview and update of its innovative current late-stage portfolio. Key highlights include: Privosegtor, a novel neuroprotective candidate which received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for optic neuritis (ON), in the PIONEER registrational program to address unmet needs for two optic neuropathies and to unlock a potential market opportunity of $7B+ in the U.S. alone, and Licaminlimab, a topical anti-TNFα being evaluated in the PREDICT-1 registrational trial as the first genotype-based precision medicine in dry eye disease (DED).

With a strong balance sheet and advanced pipeline, Oculis prepares to deliver several pivotal readouts with the current funding, focusing on fulfilling its mission to save sight and improve eye care with groundbreaking treatments.

47^th Annual Goldman Sachs Global Healthcare Conference
Date: June 9, 4:00pm ET
Location: Miami, FL
Format: Fireside chat
Presenter: Dr. Riad Sherif, CEO
Webcast link: Register here

The Company will be available for one-on-one meetings during the conference. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.

Webcast links, when available, are posted to the Oculis website on the Events & Presentations page under the Investors & Media section.

-ENDS-

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, which consists of studies intended to support registration plans for treatment of optic neuropathies, including  optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION). Privosegtor also has potential to be developed for additional indications in other neuro-ophthalmic and neurological diseases. Licaminlimab is a novel, topical anti-TNFα  in a registrational trial, and is being developed with a genotype-based approach for treating patients with dry eye disease (DED). Headquartered in Switzerland with operations in the U.S., Iceland and Switzerland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

Oculis Contacts
Sylvia Cheung, CFO
sylvia.cheung@oculis.com

Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com

Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
oculis@icrhealthcare.com

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company’s product candidates, including the initiation, timing, progress and results of current and future clinical trials, Oculis’ research and development programs, regulatory and business strategy; expected milestones; statements about market opportunity; and statements about cash runway and capital needs, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the SEC. Copies of these documents are available on the SEC’s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law

FAQ

When will Oculis (OCS) present at the 47th Annual Goldman Sachs Global Healthcare Conference?

Oculis is scheduled for a fireside chat on June 9 at 4:00 p.m. ET in Miami, FL. According to Oculis, CEO Dr. Riad Sherif will present and the company will also be available for one-on-one investor meetings during the conference.

What topics will Oculis (OCS) cover at the Goldman Sachs Global Healthcare Conference 2026?

Oculis plans to provide an overview and update of its late-stage ophthalmic portfolio. According to Oculis, the discussion will highlight Privosegtor, Licaminlimab, key registrational trials, the company’s strong balance sheet and its preparation for several pivotal clinical readouts with current funding.

How can investors access the Oculis (OCS) webcast from the 47th Goldman Sachs Global Healthcare Conference?

Investors can access the fireside chat via a webcast link after registering. According to Oculis, webcast links, when available, are posted on the company’s website under the Investors & Media section, on the Events & Presentations page.

What is Privosegtor in Oculis (OCS) pipeline and why is it important?

Privosegtor is a novel neuroprotective candidate for optic neuritis and other optic neuropathies. According to Oculis, it has FDA Breakthrough Therapy and EMA PRIME designations and is in the PIONEER registrational program, targeting a potential $7B+ U.S. market opportunity.

What is Licaminlimab and which trial will Oculis (OCS) discuss at the conference?

Licaminlimab is a topical anti-TNFα therapy for dry eye disease. According to Oculis, it is being evaluated in the PREDICT-1 registrational trial as a potential first genotype-based precision medicine in dry eye disease, and will feature in the company’s conference update.

Will Oculis (OCS) discuss its financial position during the Goldman Sachs healthcare conference?

Oculis intends to emphasize its strong balance sheet alongside clinical programs. According to Oculis, current funding is expected to support delivery of several pivotal readouts, which management will highlight while outlining progress on its late-stage ophthalmic pipeline at the conference.